

CLAIM AMENDMENTS

1(Currently Amended). A compound 8 to 50 nucleobases in length targeted to a 5'-untranslated region, a start codon region, a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule of SEQ ID NO: 3 encoding human microsomal triglyceride transfer protein, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of a nucleic acid molecule encoding human microsomal triglyceride transfer protein.

2(Original). The compound of claim 1 which is an antisense oligonucleotide.

3(Previously Canceled).

4(Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5(Original). The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6(Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7(Original). The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8(Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9(Original). The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10(Original). The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11(Currently Amended). A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule of SEQ ID NO: 3 encoding human microsomal triglyceride transfer protein, wherein said active site is a sequence spanning nucleotides 3133 to 3152 of SEQ ID NO: 3 listed in Table 1 and wherein said compound inhibits expression of said molecule encoding said protein.

12(Original). A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13(Original). The composition of claim 12 further comprising a colloidal dispersion system.

14(Original). The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15(Previously Amended). A method of inhibiting the expression of human microsomal triglyceride transfer protein in cells or tissues *in vitro* comprising contacting said cells or tissues with the compound of claim 1 so that expression of human microsomal triglyceride transfer protein is inhibited.

16-20(Previously Canceled).